APA

Daniels G. H., Hegedüs L., Marso S. P., Nauck M. A., Zinman B., Bergenstal R. M., Mann J. F. E., Derving Karsbøl J., Moses A. C., Buse J. B. & Tuttle R. M. (20160101). LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. : Diabetes, obesity & metabolism.

Chicago

Daniels G H, Hegedüs L, Marso S P, Nauck M A, Zinman B, Bergenstal R M, Mann J F E, Derving Karsbøl J, Moses A C, Buse J B and Tuttle R M. 20160101. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. : Diabetes, obesity & metabolism.

Harvard

Daniels G. H., Hegedüs L., Marso S. P., Nauck M. A., Zinman B., Bergenstal R. M., Mann J. F. E., Derving Karsbøl J., Moses A. C., Buse J. B. and Tuttle R. M. (20160101). LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. : Diabetes, obesity & metabolism.

MLA

Daniels G H, Hegedüs L, Marso S P, Nauck M A, Zinman B, Bergenstal R M, Mann J F E, Derving Karsbøl J, Moses A C, Buse J B and Tuttle R M. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. : Diabetes, obesity & metabolism. 20160101.